Brief: Rovi Sees Its 2024 EBITDA Levels To Be Lower Than Market Consensus

Laboratorios Farmaceuticos Rovi

07/02/2025 06:41

Feb 7 (Reuters) - Laboratorios Farmaceuticos ROVI SA  ROVI.MC :
    * SEES 2024 EBITDA LEVELS TO BE LOWER, WITHIN RANGE OF BETWEEN 10% AND 15%, THAN 2024 EBITDA
LEVELS ACCORDING TO MARKET CONSENSUS
    * REVISION OF MARKET CONSENSUS IN RELATION TO EBITDA IS DUE TO LOWER EXPECTED ACTIVITY IN
CONTRACT
MANUFACTURING BUSINESS (CDMO) IN Q4
    * MAINTAINS GUIDANCE FOR 2025

Source text:  ID:nCNM8rbJpZ 
Further company coverage:  ROVI.MC 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))